CMP as on 04-Jul-22 15:16₹ 281.25
Turnover (lac)₹ 1
Prev. Close₹ 278.40
Day's Vol (shares)₹ 378
Day's Range (₹)
CMP as on04-Jul-22 15:29₹ 285.00
Prev. Close₹ 284.50
Day's Vol (shares)₹ 746
The rating on long-term bank facilities has been revised to CARE BBB- (CWD) and short-term rating CARE A3 (CWD).
14,803 Global Depository Receipts of the company have been delisted from the Luxembourg Stock Exchange with effect from November 15, 20
The rating on long-term bank facilities of the company has been revised to CARE BBB -; Stable.
The total number of GDRs has reduced from 32,26,688 constituting 3.63% of the total paid-up share capital to 14,803 GDRs constituting 0
The consideration for the transaction is estimated to be up to Rs170cr ina combination of cash and equity stake in the Joint Venture Co
The rating assigned on short-term bank facilities of the pharmacy company is CARE A4+.
The company is confident that in the normal course of its business, it may raise financial resources, from time to time.
Orchid Pharma has received ANDA approval from USFDA for Risedronate Sodium Tablets USP, 30 mg and 35 mg.
Lately, Indian pharma companies have been increasingly receiving EIRs and clearing USFDA audits, however, investors should always be wa
While the EU GMP certificate is positive, company is referred to bankruptcy.
Per Order for ETF & Mutual Funds Brokerage
Per Order for Delivery, Intraday, F&O, Currency & Commodity